THE 60-SECOND GUIDE
Liraglutide
Approved human use · product-specific labels.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
Liraglutide is a GLP-1 receptor agonist used in separately labeled medicines for type 2 diabetes and chronic weight management. Its glucose and appetite effects come with product-specific eligibility, warnings, and limitations. [1]
Potential benefits
Approved products support glycemic control or chronic weight management under separate labels. Its engineered structure extends GLP-1 receptor activity. [1]
Evidence & its limits
Evidence for a diabetes product does not automatically establish every weight-management claim. Liraglutide products carry significant warnings, including thyroid C-cell tumor concerns; gastrointestinal effects and pancreatitis, gallbladder, and kidney-related precautions also require attention to the applicable label. [1]
Risks & unknowns
Gastrointestinal effects are common. Contraindications, interactions, and boxed-warning context must follow the exact product. [1]
Status & scope
Approved human use · product-specific labels. Read the full record for product, formulation and indication-specific status; a biological role or measured response is not a treatment approval. [1]
November 2026 safety update
FDA requires a warning about a potential increased risk of NAION, a rare optic-nerve condition that can cause permanent vision loss. Seek prompt medical attention for sudden painless vision loss or other visual changes. Individual labels may still be undergoing revision. [4]
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- FDA Drugs@FDA database
- FDA clinical review: liraglutide approval history
- FDA · GLP-1 eye-safety notice · November 9, 2026
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.